Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: A 9-year follow-up study

Hypertension

Volumn 62, Issue 5, 2013, Pages 860-865

  Cannone, Valentina ^a   Huntley, Brenda K ^a   Olson, Timothy M ^b   Heublein, Denise M ^a   Scott, Christopher G ^a   Bailey, Kent R ^a   Redfield, Margaret M ^a   Rodeheffer, Richard J ^a   Burnett, John C ^a  

^a MAYO CLINIC   (United States)

^b Cardiovascular Genetics Research Laboratory   (United States)

Author keywords

atrial natriuretic peptides; cardiovascular diseases; natriuretic peptidesstroke

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; ATRIAL NATRIURETIC FACTOR RECEPTOR;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMMUNITY; EMBRYO; ENDOTHELIUM CELL; FLUORESCENCE; FOLLOW UP; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; PERMEABILITY; RISK; SECOND MESSENGER; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR DISEASES; CYCLIC GMP; ENDOTHELIAL CELLS; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; PERMEABILITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; RECEPTORS, GUANYLATE CYCLASE-COUPLED; RISK; SECOND MESSENGER SYSTEMS;

EID: 84886412379     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01344     Document Type: Article

References (32)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28:89-94.
2. Garbers DL, Chrisman TD, Wiegn P, Katafuchi T, Albanesi JP, Bielinski V, Barylko B, Redfield MM, Burnett JC Jr. Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab. 2006;17:251-258.
3. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab. 2008;19:130-137.
4. Curry FR. Atrial natriuretic peptide: an essential physiological regulator of transvascular fluid, protein transport, and plasma volume. J Clin Invest. 2005;115:1458-1461.
5. Schreier B, Börner S, Völker K, Gambaryan S, Schäfer SC, Kuhlencordt P, Gassner B, Kuhn M. The heart communicates with the endothelium through the guanylyl cyclase-A receptor: acute handling of intravascular volume in response to volume expansion. Endocrinology. 2008;149:4193-4199.
6. Lofton CE, Newman WH, Currie MG. Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP. Biochem Biophys Res Commun. 1990;172:793-799.
7. Zimmerman RS, Trippodo NC, MacPhee AA, Martinez AJ, Barbee RW. High-dose atrial natriuretic factor enhances albumin escape from the systemic but not the pulmonary circulation. Circ Res. 1990;67:461-468.
8. Sabrane K, Kruse MN, Fabritz L, Zetsche B, Mitko D, Skryabin BV, Zwiener M, Baba HA, Yanagisawa M, Kuhn M. Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. J Clin Invest. 2005;115:1666-1674.
9. Newton-Cheh C, Larson MG, Vasan RS, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41:348-353.
10. Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58:629-636.
11. Cannone V, Cefalu AB, Noto D, Scott CG, Bailey KR, Cavera G, Pagano M, Sapienza M, Averna MR, Burnett JC Jr. The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a mediterranean population. Diabetes Care. 2013;36:2850-2856.
12. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, Tarasi D, Gigante B, Pirisi A, Brunetti E, Volpe M. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke. 2004;35:814-818.
13. Gruchala M, Ciećwierz D, Wasag B, Targoński R, Dubaniewicz W, Nowak A, Sobiczewski W, Ochman K, Romanowski P, Limon J, Rynkiewicz A. Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J. 2003;145:125-131.
14. Zhang L, Cheng L, He M, Hu B, Wu T. ANP T2238C, C-664G gene polymorphism and coronary heart disease in chinese population. J Huazhong Univ Sci Technolog Med Sci. 2006;26:528-530.
15. Barbato E, Bartunek J, Mangiacapra F, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol. 2012;59:1763-1770.
16. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, Savoia C, Quarta G, Sciarretta S, Ruco L, Volpe M, Rubattu S. Reactive oxygen species-mediated effects on vascular remodeling induced by human atrial natriuretic peptide T2238C molecular variant in endothelial cells in vitro. J Hypertens. 2009;27:1804-1813.
17. van Nieuw Amerongen GP, van Hinsbergh VW. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vascul Pharmacol. 2002;39:257-272.
18. van Hinsbergh VW. Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol. 1997;17:1018-1023.
19. Nielsen LB. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis. 1996;123:1-15.
20. Colangelo S, Langille BL, Steiner G, Gotlieb AI. Alterations in endothelial F-actin microfilaments in rabbit aorta in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1998;18:52-56.
21. Lynch AI, Claas SA, Arnett DK. A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae. Curr Hypertens Rep. 2009;11:35-42.
22. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, Sone M, Yamahara K, Taura D, Inuzuka M, Sonoyama T, Nakao K. Natriuretic peptides/cGMP/cGMP- dependent protein kinase cascades promote muscle mitochondrial biogenesis and prevent obesity. Diabetes. 2009;58:2880-2892.
23. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
24. Ellis KL, Newton-Cheh C, Wang TJ, Frampton CM, Doughty RN, Whalley GA, Ellis CJ, Skelton L, Davis N, Yandle TG, Troughton RW, Richards AM, Cameron VA. Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol. 2011;50:695-701.
25. Nannipieri M, Manganiello M, Pezzatini A, De Bellis A, Seghieri G, Ferrannini E. Polymorphisms in the hANP (human atrial natriuretic peptide) gene, albuminuria, and hypertension. Hypertension. 2001;37:1416-1422.
26. Rahmutula D, Nakayama T, Soma M, Takahashi Y, Kunimoto M, Uwabo J, Sato M, Izumi Y, Kanmatsuse K, Ozawa Y. Association study between the variants of the human ANP gene and essential hypertension. Hypertens Res. 2001;24:291-294.
27. Kato N, Sugiyama T, Morita H, Nabika T, Kurihara H, Yamori Y, Yazaki Y. Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. Clin Sci (Lond). 2000;98:251-258.
28. Rutledge DR, Sun Y, Ross EA. Polymorphisms within the atrial natriuretic peptide gene in essential hypertension. J Hypertens. 1995;13:953-955.
29. Zorc-Plesković R, Bidovec M, Bregar D, Milutinović A, Terzić R, Teran N. The ScaI gene polymorphism of the atrial natriuretic factor and essential arterial hypertension in childhood. Coll Antropol. 2004;28:617-621.
30. Nkeh B, Tiago A, Candy GP, Woodiwiss AJ, Badenhorst D, Luker F, Netjhardt M, Brooksbank R, Libhaber C, Sareli P, Norton GR. Association between an atrial natriuretic peptide gene polymorphism and normal blood pressure in subjects of African ancestry. Cardiovasc J S Afr. 2002;13:97-101.
31. Niu W. The relationship between natriuretic peptide precursor a gene T2238C polymorphism and hypertension: a meta-analysis. Int J Hypertens. 2011;2011:653698.
32. Sciarretta S, Marchitti S, Bianchi F, Moyes A, Barbato E, Di Castro S, Stanzione R, Cotugno M, Castello L, Calvieri C, Eberini I, Sadoshima J, Hobbs AJ, Volpe M, Rubattu S. C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res. 2013;112:1355-1364.